TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06409104
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: will receive dexmedetomidine at a loading dose of 1 μg/kg over 10 min, followed by a 0.2-0.7-μg/kg/h infusion.
Study: NCT06561633
Drug: Sugammadex administration
DrugBank: Sugammadex (DB06206)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: After surgery was completed while the train-of-four ratio was zero, a steady-state intravenous anesthesia was maintained to keep a BIS value within the range of 40-60 for at least 5 minutes. Patients received sugammadex 2 mg.kg-1 after completed surgery.
Study: NCT04851132
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Durvalumab 1000 mg, intravenously (IV), on Day 1 of radiotherapy, every 3 weeks for up to 18 administrations.
Study: NCT05427500
Drug: 5 mL of 0.5% preservative-free bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV will be inserted. Patient will be connected to cardiorespiratory monitors. The neck will be cleansed twice. A high frequency (15-6 MHz) linear ultrasound probe will be used to identify the arteries, jugular vein, and other important vasculature. Once a clear path for the needle is identified, the skin is anesthetized. A cutting tip spinal needle is then inserted at the lateral aspect of the field and advanced in-plane under ultrasound visualization. A test injection is injected to verify placement, then 5 mL of 0.5% preservative-free bupivacaine will be injected. Per standard SGB procedure, vitals will be measured post-SGB and participants will remain in the clinic for approximately 15 minutes to monitor for any serious adverse events.
Study: NCT04864054
Drug: Regorafenib (STIVARGA®, BAY73-4506)
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Regorafenib pretreatment before an ECT204 infusion.
Study: NCT05052853
Drug: NMDAE
Normalized name: NMDA
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Use of an NMDA enhancer for the treatment of prodromal schizophrenia .
Study: NCT05493293
Drug: NBI-921352
Normalized name: NBI-98782
DrugBank: NBI-98782 (DB16905)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets for oral administration
Study: NCT04659707
Drug: Hyperpolarized Xe129
Normalized name: xenon-129, hyperpolarized
DrugBank: Xenon (DB13453)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will inhale up to 4 doses of hyperpolarized Xenon gas in order to image pulmonary function.
Study: NCT04777760
Drug: one dose of surfactant replacement
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: the preterm infants diagnosed with NRDS and/or NARDS will be administrated with only one dose of surfactant
Study: NCT06504576
Drug: Cilostazol 50 MG Oral Tablet
Normalized name: cilostazol 50 MG Oral Tablet
DrugBank: Cilostazol (DB01166)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Two consecutive weeks of Cilostazol (50mg BID) two days after admission
Study: NCT05101018
Drug: Romosozumab
Normalized name: ROMOSOZUMAB
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Romosozumab (Amgen Inc., Thousand Oaks, CA) 210mg SQ administered each month
Study: NCT05101018
Drug: Denosumab
Normalized name: Denosumab
DrugBank: Denosumab (DB06643)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Denosumab (Amgen Inc., Thousand Oaks, CA) 60 mg SQ administered every six months
Study: NCT06123702
Drug: Cannabidiol Cap/Tab
Normalized name: CANNABIDIOL CAP/TAB
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 12 50-mg capsules
Study: NCT05304845
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: acetylsalicylic acid
Study: NCT04814485
Drug: SHR-1020+albumin-bound paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: SHR-1020 combined with albumin-bound paclitaxel for advanced pancreatic cancer
Study: NCT05572645
Drug: Pyrotinib Plus Trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: treatment based on Pyrotinib(320-400 mg, po, qd) Plus Trastuzumab(8 mg/kg q3w, and then 6 mg/kg q3w)
Study: NCT05572645
Drug: Pertuzumab Plus Trastuzumab
Normalized name: hyaluronidase / pertuzumab / trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: treatment based on Pertuzumab(840mg q3w, and then 420 mg q3w) Plus Trastuzumab(8 mg/kg q3w, and then 6 mg/kg q3w)
Study: NCT00215397
Drug: Formoterol Fumarate
Normalized name: Formoterol Fumarate
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT05857267
Drug: Dorzolamide / Timolol Ophthalmic Solution
Normalized name: dorzolamide / timolol Ophthalmic Solution
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dorzolamide-timolol fixed combination in a preservative-free multidose device
Study: NCT05857267
Drug: dorzolamide/timolol
Normalized name: DORZOLAMIDE/TIMOLOL
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dorzolamide-timolol BAK-preserved fixed combination
Study: NCT00537953
Drug: Miltefosine , meglumine antimoniate
DrugBank: Miltefosine (DB09031)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05893862
Drug: MK-8189
Normalized name: MK-8189
DrugBank: MK-8189 (DB19153)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Tablet
Study: NCT05893862
Drug: Moxifloxacin
Normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Tablet
Study: NCT06354218
Drug: Serplulimab
Normalized name: Serplulimab
DrugBank: Serplulimab (DB17451)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serplulimab （4.5mg/Kg every 3 weeks）
Study: NCT05627518
Drug: Linaprazan glurate
Normalized name: calcium glucarate
DrugBank: Calcium saccharate (DB13962)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg
Study: NCT05947669
Drug: Infliximab
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab is available in vials of 100 mg with pharmaceutical form of concentrate for solution for infusion. Participating sites will ensure availability of infliximab as part of the hospital's standard supply for use in the study.
Study: NCT05947669
Drug: Methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone is available in vials of 40 mg. Methylprednisolone is a drug used for standard treatment first line for ir-colitis or diarrhoea CTCAE grade ≥ 3. Participating sites will ensure availability of methylprednisolone for use in the study as part of the hospitals standard supply.
Study: NCT05705830
Drug: Selective serotonin reuptake inhibitors （SSRI）
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-anxiety Drugs
Study: NCT06281899
Drug: Dapagliflozin 10 mg Tab
Normalized name: dapagliflozin
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dapagliflozin 10 mg once daily
Study: NCT04723238
Drug: Duloxetine 60mg Test Drug Enteric Coated Granules
Normalized name: duloxetine
DrugBank: Duloxetine (DB00476)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Investigational Medicinal Product
Study: NCT04723238
Drug: Duloxetine 60mg Reference Product Enteric Coated Granules
Normalized name: duloxetine
DrugBank: Duloxetine (DB00476)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cymbalta (Eli Lilly)
Study: NCT04715165
Drug: USG-STAP with bupivacaine and dexmedetomidine
Normalized name: bupivacaine and meloxicam
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive USG-STAP block with bupivacaine and dexmedetomidine in both sides ten minutes before skin incision and intraperitoneal normal saline
Study: NCT04715165
Drug: IP bupivacaine and dexmedetomidine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive bupivacaine and dexmedetomidine through the intraperitoneal route and USG-STAP block with normal saline at the end of surgery
Study: NCT05027633
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: given by IV
Study: NCT05027633
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: given by IV
Study: NCT05027633
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: given by IV
Study: NCT05027633
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: given by IV
Study: NCT05804370
Drug: Gleolan
Normalized name: Gleolan
DrugBank: Aminolevulinic acid (DB00855)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gleolan is a prodrug that is metabolized intracellularly to form the fluorescent molecule Protoporphyrin IX (PpIX). The oral provision of Gleolan leads to a highly selective accumulation of PpIX in tumor cells. Following excitation with blue light (BL) (wavelength \[λ\] = 375 - 450 nm), the PpIX, which has accumulated selectively in tumor tissue, emits a red-violet light.
Study: NCT06385171
Drug: Botulinum toxin type A
Normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: The intervention involves the administration of Botulinum Toxin Type A, with dosages regulated according to FDA guidelines. Each injection site will receive a maximum of 4 units, adhering to the FDA's recommended dosage limits. Dosages administered will be tailored to each patient's needs and will be recorded in their individual patient information chart.
Study: NCT05994547
Drug: Byfavo
Normalized name: Byfavo
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: For induction and maintenance of sedation
Study: NCT05994547
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: For induction and maintenance of sedation
Study: NCT04731103
Drug: Abacavir (ABC)
DrugBank: Abacavir (DB01048)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tablets or oral solution
Study: NCT04731103
Drug: Lamivudine (3TC)
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tablet or oral solution
Study: NCT04731103
Drug: Abacavir (ABC)+Lamivudine (3TC)+Zidovudine (AZT)
Normalized name: abacavir / lamivudine / zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet or oral solution
Study: NCT00000719
Drug: Zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000719
Drug: Zalcitabine
Normalized name: Zalcitabine
DrugBank: Zalcitabine (DB00943)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05562167
Drug: KNO3
Normalized name: Potassium Nitrate
DrugBank: Potassium citrate (DB09125)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 10 mmol of KNO3 via a single gel capsule to be consumed orally once per day for 6 weeks.
Study: NCT04887064
Drug: Sotorasib
Normalized name: SOTORASIB
DrugBank: Sotorasib (DB15569)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sotorasib will be administered as an oral tablet.
Study: NCT04743791
Drug: Dupilumab
Normalized name: Dupilumab
DrugBank: Dupilumab (DB12159)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dupilumab is supplied as a sterile aqueous solution for SC injection at the concentration of 175 mg/mL in glass pre-filled syringe to deliver 200 mg in 1.14mL.
Study: NCT04777201
Drug: Faricimab
Normalized name: Faricimab
DrugBank: Faricimab (DB15303)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Faricimab 6 mg will be administered by intravitreal (IVT) injection into the study eye according to the personalized treatment interval (PTI) dosing regimen for the duration of the study.
Study: NCT06420388
Drug: 2% Lidocaine Gel
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The intervention group received 5 mL of 2% lidocaine gel applied topically 3 times per day after undergoing Ferguson hemorrhoidectomy surgery.~The control group received 5 mL of a non-anesthetic water-based lubricant gel applied topically 3 times per day after surgery.~The application of the gels began immediately after surgery and continued for the postoperative period evaluated in the study.~Both groups received standard postoperative analgesics (acetaminophen, celecoxib, Dynastat/parecoxib as needed) in addition to the topical gel applications.
Study: NCT06420388
Drug: Water-based Lubricant Gel (K-Y Gel)
Normalized name: benzoyl peroxide
DrugBank: Water (DB09145)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The intervention group received 5 mL of mL of a non-anesthetic water-based lubricant gel (K-Y gel) applied topically 3 times per day after undergoing Ferguson hemorrhoidectomy surgery.
Study: NCT04617275
Drug: PF-06882961
Normalized name: PF-06882961
DrugBank: PF-06882961 (DB16043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-68882961 will be provided as tablets twice a day (BID)
Study: NCT05922501
Drug: Isatuximab
Normalized name: Isatuximab
DrugBank: Isatuximab (DB14811)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: An IgG1-derived monoclonal antibody that targets CD38 proteins, administered intravenously.
Study: NCT05922501
Drug: Belantamab mafodotin
Normalized name: belantamab mafodotin
DrugBank: Belantamab mafodotin (DB15719)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: An antibody-drug conjugate that is the combination of an antibody targeting BCMA and a drug, administered intravenously.
Study: NCT05922501
Drug: Pomalidomide
Normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: An immunomodulatory agent, capsule taken orally.
Study: NCT05922501
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: A glucocorticoid which is a substance that stops inflammation cause by immune system disorders, tablet taken orally.
Study: NCT00269945
Drug: epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06109389
Drug: Lidocaine IV
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: LIDOCAINE INFUSION STARTED 3 MG PER KG FOR 2 SUCCESSIVE WEEKS ,THEN 4 MG PER KG FOR ANOTHER 2 WEEKS .ONCE WEEKLY,other group saline infusion once weekly for 4 successive weeks
Study: NCT05061420
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pharmaceutical Form: Concentration for solution for infusion Route of Administration: Intravenous Infusion
Study: NCT05061420
Drug: Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pharmaceutical Form: Solution for infusion Route of Administration: Intravenous Infusion
Study: NCT05119179
Drug: Semaglutide
Normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Glucagon-like Peptide 1 Receptor Agonist
Study: NCT06071897
Drug: monoclonal antibodies GD2
Normalized name: CHIMERIC ANTI-DISIALOGANGLIOSIDE (GD2) MONOCLONAL ANTIBODY (CH14.18/CHO)
DrugBank: Dinutuximab (DB09077)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Main target of this trial is to estimate tolerability and toxicity of combination of standard chemotherapy (N5 and N6) with anti-GD2 MAB~N5Q. N5 (see above) Dinutuximab beta 10 mg/m2 i.v., days 5-9\*~N6Q. N6 (see above) Dinutuximab beta 10 mg/m2 i.v., days 6-10\*~G-CSF (granulocyte colony-stimulating factor) 5 mcg/kg s.c. on day 9 until the ANC is more than 2000 /ml or until counts have recovered for the next cycle of therapy
Study: NCT06729047
Drug: Neostigmine
Normalized name: Neostigmine
DrugBank: Neostigmine (DB01400)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patients will receive neostigmine (40 μg/kg) plus atropine (20 μg/kg)
Study: NCT06727838
Drug: HRS-7535 tablets
Normalized name: HRS-1167
DrugBank: HRS-1167 (DB18703)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRS-7535 tablets.
Study: NCT06727838
Drug: Metformin Hydrochloride Extended-release Tablets
Normalized name: Metformin Hydrochloride Extended-Release Tablets
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin Hydrochloride Extended-release Tablets.
Study: NCT06727838
Drug: Metformin Hydrochloride Tablets
Normalized name: Metformin Hydrochloride Tablets
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin Hydrochloride Tablets.
Study: NCT06728839
Drug: 1L PEG + 50g magnesium sulfate
Normalized name: PEG
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects in Group A will use a regimen combining magnesium sulfate and polyethylene glycol for preoperative bowel preparation and undergo colonoscopy. 1 litter of polyethylene glycol is taken at 8pm the day before the colonoscopy and 50 gram of magnesium sulfate is taken 4-6 hours before the colonoscopy, and then drink 2000 ml of water within 2 hours.
Study: NCT06728839
Drug: 3L PEG
Normalized name: PEG
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects in Group B will use a regimen with 3L polyethylene glycol for preoperative bowel preparation and undergo colonoscopy. The 3 liters of polyethylene glycol solution is taken in split dosing, with 1 liter taken at 8pm the day before the colonoscopy and 2 liters taken 4-6 hours before the colonoscopy.
Study: NCT06728839
Drug: 4L PEG
Normalized name: PEG
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects in Group C will use a regimen with 4L polyethylene glycol for preoperative bowel preparation and undergo colonoscopy. The 4 liters of polyethylene glycol solution is taken in split dosing, with 2 liters taken at 8pm the day before the colonoscopy and 2 liters taken 4-6 hours before the colonoscopy.
Study: NCT06729034
Drug: Apixaban (Eliquis)
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 5 mg twice daily
Study: NCT06729086
Drug: sedation using propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The different complications studied will be for example respiratory, neurologic and cardiac based on several clinical and biological parameters.
Study: NCT06729086
Drug: sedation using sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The differents complications studied will be for example respiratory, neurologic and cardiac based on severl clinical and biological parameters.
Study: NCT04745104
Drug: SHR-1707
Normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR-1707 will be administered through IV infusion
Study: NCT05746208
Drug: Lenvatinib
Normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given orally
Study: NCT05746208
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT01446120
Drug: NPH-Insulin Injection
Normalized name: Neutral Protamine Hagedorn (NPH) insulin
DrugBank: Neutral Protamine Hagedorn (NPH) insulin (DB18001)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05043766
Drug: PF614
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: PF614 is an oxycodone prodrug
Study: NCT05043766
Drug: Naltrexone Hydrochloride
Normalized name: Naltrexone Hydrochloride
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naltrexone HCl tablets, 50 mg, will be used to block the opioid effects in healthy volunteers
Study: NCT05043766
Drug: OxyContin
Normalized name: Oxycontin
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Bioequivalence single-dose comparison to OxyContin
Study: NCT04071470
Drug: PrEP
Normalized name: X-Prep
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients at risk of HIV acquisition will be provided PrEP medications and counseling in ANC
Study: NCT06160713
Drug: Itraconazole 65 MG
Normalized name: itraconazole 65 MG
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Two capsules of suba-itraconazole 65 mg twice daily for 6 months
Study: NCT06426212
Drug: Use of teicoplanin three times a week
Normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
Approvals — FDA: no, EMA: no, PMDA: no
Description: retrospective study to evaluate the clinical effectiveness of teicoplanin therapy according to a three-weekly scheme comparing its use in the treatment of deep infections (deep seated infections - DSIs) and superficial infections (non-deep seated infections - NDSIs).
Study: NCT06455735
Drug: 68Ga-JH04
Normalized name: 68Ga-DOTATOC
DrugBank: Dotatate gallium Ga-68 (DB13925)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of one dosage of 111-148 MBq (3-4 mCi) 68Ga-JH04. Tracer doses of 68Ga-JH04 will be used to detect tumors by PET/CT.
Study: NCT06030804
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: A loading dose of dexmedetomidine (0.6 μg/kg) will be administered over 10-15 minutes before anaesthesia induction, followed by a continuous infusion at a rate of 0.5 μg/kg/hr till 1 hour before the end of surgery. Patient-controlled dexmedetomidine supplemented sufentanil analgesia will be provided after surgery: the formula contains a mixture of sufentanil (1.25 μg/ml) and dexmedetomidine (1.25 μg/ml), diluted with normal saline to a total volume of 160 ml; the analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with patient-controlled bolus of 2 ml each time and a lockout time of 8 minutes.
Study: NCT06010277
Drug: Folinic acid
Normalized name: Folinic acid
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Follow-up will take place during the first 4 cycles of chemotherapy with pemetrexed. Patients in the intervention-arm will receive oral folinic acid orally 4 times 45mg / day for 3 days, starting 24 hours after the administration of pemetrexed.
Study: NCT02652325
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02652325
Drug: Povidone-Iodine
Normalized name: Povidone-Iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02652325
Drug: 5% Povidone-Iodine USP swabs
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04807673
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Neoadjuvant period: paclitaxel 135mg/m\^2 IV on Day 2 Q3W, and a total of three cycles.
Study: NCT04807673
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neoadjuvant period: cisplatin 80 mg/m\^2 IV on Day 2 Q3W, and a total of three cycles.